Ilex/Millennium Campath
Executive Summary
Phase II multiple sclerosis and kidney transplant clinical trials are being evaluated for 2001, but plans have not been set. At UBS Warburg conference, Ilex Oncology CEO Richard Love incorrectly indicated the drug would be entering Phase III for kidney transplants and MS (1"The Pink Sheet" Oct. 9, p. 23)
You may also be interested in...
Ilex Resembles Recent Biotech Acquisition Targets As Campath Nears Market
Ilex Oncology appears to fit the profile of recently acquired companies within the biotechnology industry.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials